Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors

Sub-retinal fluid (SRF) has been discussed as a protective factor against macular atrophy in eyes with neovascular age-related macular degeneration (nAMD).To gauge the impact of SRF on macular atrophy, a database of 310 nAMD eyes was screened for eyes manifesting an SRF-only phenotype under treat &a...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2020-05, Vol.10 (1), p.8036-8036, Article 8036
Main Authors: Siedlecki, Jakob, Fischer, Cheryl, Schworm, Benedikt, Kreutzer, Thomas C, Luft, Nikolaus, Kortuem, Karsten U, Schumann, Ricarda G, Wolf, Armin, Priglinger, Siegfried G
Format: Article
Language:English
Subjects:
Age
Aged
Aged, 80 and over
Angiogenesis Inhibitors - pharmacology
Angiogenesis Inhibitors - therapeutic use
Angiography
Atrophy
Disease Susceptibility
Eye
Female
Follow-Up Studies
Humans
Incidence
Macula Lutea - diagnostic imaging
Macula Lutea - drug effects
Macula Lutea - metabolism
Macula Lutea - pathology
Macular degeneration
Macular Degeneration - diagnosis
Macular Degeneration - epidemiology
Macular Degeneration - metabolism
Macular Degeneration - therapy
Male
Middle Aged
Multimodal Imaging
Phenotypes
Prevalence
Retina
Subretinal Fluid - metabolism
Treatment Outcome
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sub-retinal fluid (SRF) has been discussed as a protective factor against macular atrophy in eyes with neovascular age-related macular degeneration (nAMD).To gauge the impact of SRF on macular atrophy, a database of 310 nAMD eyes was screened for eyes manifesting an SRF-only phenotype under treat & extend anti-VEGF treatment, defined as nAMD expressing CNV exudation beyond the three monthly anti-VEGF loading doses by SRF only without any signs of exudative intra-retinal fluid (IRF) for ≥3 years. Incidence of macular atrophy and treatment responses were evaluated on multimodal imaging, including optical coherence tomography (OCT), blue autofluorescence (BAF) and near-infrared (NIR) confocal scanning laser ophthalmoscopy and fluorescence and indocyanine green angiography (FAG/ICGA). In total, 27 eyes (8.7%) of 26 patients with a mean follow-up of 4.2 ± 0.9 (3-5) years met the inclusion criteria. Mean age was 72 ± 6 (range: 61-86) years. The SRF only phenotype was seen from baseline in 14 eyes (52%), and in 13 eyes (48%) after a mean 1.0 ± 1.3 (1-3) injections. In years 1 to 5, mean 7.5, 5.9, 6.1, 6.1 and 7.0 anti-VEGF injections were given (p = 0.33). Cumulative macular atrophy incidence was 11.5% at year 1, 15.4% throughout years 2 to 4, and 22.4% at year 5. In conclusion, eyes manifesting activity by SRF only in treat & extend anti-VEGF regimen for nAMD seem to exhibit rather low rates of macular atrophy during long-term follow-up. SRF might be an indicator of a more benign form of nAMD.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-020-64901-9